PMID- 28033252
OWN - NLM
STAT- MEDLINE
DCOM- 20170215
LR  - 20220311
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 52
DP  - 2016 Dec
TI  - 18F-FDG super bone marrow uptake: A highly potent indicator for the malignant 
      infiltration.
PG  - e5579
LID - 10.1097/MD.0000000000005579 [doi]
LID - e5579
AB  - The present study was performed to investigate whether the markedly 
      2-deoxy-2-(fluorine-18) fluoro-D-glucose (F-FDG) uptake in the bone marrow (BM) 
      is a presentation of malignant infiltration (MI).Super bone marrow uptake (super 
      BMU) was used to name the markedly F-FDG uptake on BM, which was similar to or 
      higher than that of the brain. From April 2008 to December 2015, 31 patients with 
      such presentation were retrospectively reviewed. The F-FDG uptake was 
      semiquantified using SUVmax and BM to cerebellum (BM/C) ratio. The origin of 
      super BMU was diagnosed by pathology. Some blood parameters, as well as fever, 
      were also collected and analyzed. For comparison, 106 patients with mildly and 
      moderately uptake in BM and 20 healthy subjects were selected as the control 
      group.Bone marrow MI was diagnosed in 93.5% (29/31) patients with super BMU, 
      which mostly originated from acute leukemia and highly aggressive lymphoma. The 
      super BMU group had markedly higher F-FDG uptake in the BM than those of mildly 
      and moderately uptake, and the control subjects (all P = 0.000) and the BM/C 
      ratio reached a high of 1.24 +/- 0.36. The incidence of bone marrow MI in the super 
      BMU group was markedly higher than that of mildly and moderately uptake (93.5% vs 
      36.8%, P = 0.000). Based on the receiver operating characteristic analysis, when 
      cut-off values of BM/C and SUVmax were set at 0.835 and 6.560, the diagnostic 
      specificity for bone marrow MI reached the high levels of 91.4% and 95.7%, 
      respectively. In 15 patients with bone marrow MI, the extra-BM malignant lesions 
      were simultaneously detected by F-FDG PET/CT. The liver and the nasal cavity 
      involvements were only found in the patients with lymphoma, but not in those with 
      leukemia. A decrease of leukocyte, hemoglobin, and platelet counts was noted in 
      48.4%, 86.2%, and 51.5% of patients with bone marrow MI, respectively.The present 
      study revealed that super BMU was a highly potent indicator for the bone marrow 
      MI.
FAU - Alam, Mohammed Shah
AU  - Alam MS
AD  - NanFang PET Center, Nanfang Hospital, Southern Medical University, Guangzhou, 
      China.
FAU - Fu, Lilan
AU  - Fu L
FAU - Ren, Yun-Yan
AU  - Ren YY
FAU - Wu, Hu-Bing
AU  - Wu HB
FAU - Wang, Quan-Shi
AU  - Wang QS
FAU - Han, Yan-Jiang
AU  - Han YJ
FAU - Zhou, Wen-Lan
AU  - Zhou WL
FAU - Li, Hong-Sheng
AU  - Li HS
FAU - Wang, Zhen
AU  - Wang Z
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Hemoglobins)
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Bone Marrow/*diagnostic imaging/metabolism
MH  - Bone Neoplasms/blood/*diagnostic imaging/secondary
MH  - C-Reactive Protein/metabolism
MH  - Child
MH  - Female
MH  - Fever/blood/diagnostic imaging
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - L-Lactate Dehydrogenase/blood
MH  - Leukemia/blood/*diagnostic imaging
MH  - Leukocyte Count
MH  - Lymphoma/blood/*diagnostic imaging
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/blood/diagnostic imaging
MH  - Platelet Count
MH  - Positron Emission Tomography Computed Tomography
MH  - ROC Curve
MH  - Radiopharmaceuticals/*pharmacokinetics
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC5207548
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2016/12/30 06:00
MHDA- 2017/02/16 06:00
PMCR- 2016/12/30
CRDT- 2016/12/30 06:00
PHST- 2016/12/30 06:00 [entrez]
PHST- 2016/12/30 06:00 [pubmed]
PHST- 2017/02/16 06:00 [medline]
PHST- 2016/12/30 00:00 [pmc-release]
AID - 00005792-201612300-00010 [pii]
AID - MD-D-16-05650 [pii]
AID - 10.1097/MD.0000000000005579 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 Dec;95(52):e5579. doi: 10.1097/MD.0000000000005579.